In the "2018 Golden Hong Kong Stocks Annual Awards Ceremony and Hong Kong Listed Companies Roadshow" event, CSPC was shortlisted for the list of the most valuable pharmaceutical and medical stock companies.
On January 4, CSPC and Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd. entered into an agreement on the cooperative development and strategic cooperation of five small molecule compounds developed by Hangzhou Inchuang.
On January 4, CSPC and Yongshun Technology signed an agreement to acquire all issued shares of Yongshun Technology for RMB 258.8 million.
On January 16, CSPC was listed on the "2018 Top 100 Chinese Manufacturing Enterprise Credit".
CSPC won the "2018 Most Innovative Enterprise Award in the Great Health Industry".
"Institutional Investor" magazine announced the latest annual rankings, and CSPC was named the "most respected company" in 164 healthcare and pharmaceutical groups.
CSPC was selected as the World's Best Employer List 2018.
CSPC and Verastem entered into an exclusive product license and cooperation agreement.
CSPC obtained the authorization of monoclonal antibody products from China Cell Engineering Corporation.
CSPC ranked second in the top 20 most competitive pharmaceutical listed companies in China in 2018.
CCTV ’s English Channel (CGTN) ’s“ Global Look ”column broadcasts the status of patented and innovative medicines represented by EmbiP. The news states that The story of CSPC is a telling chapter of how Chinese people invent and use technology.
CSPC was shortlisted as one of the "Top 1000 Global Innovation Companies" selected by PricewaterhouseCoopers.
At the pre-conference of the 12th China Pharmaceutical Preparations Conference in 2018, the launch of the excellent project of innovative preparations, CSPC's anti-tumor product Ke Aili won the 2018 China's most innovative preparation variety.
On May 4, Hang Seng Index Co., Ltd. announced that as of March 30, 2018, the results of the review of the Hang Seng Index Series, CSPC (01093.HK) joined the Hang Seng Index constituent stocks. CSPC became the first pharmaceutical stock in the past 50 years to compile the Hang Seng Index.
Butylphthalein has been awarded the FDA's Orphan Drug Designation for Amyotrophic Lateral Sclerosis (ALS).
The antibody-conjugated drug was granted FDA orphan drug status for gastric cancer, including gastroesophageal junction tumors.
"Paclitaxel for injection (albumin-binding type)" obtained the first copy of the drug registration.
Acquired Wuhan Youzhiyou Biopharmaceutical Co., Ltd. to further develop biomedicine.
The US phase II clinical trial of butylphthalide soft capsules was officially launched.
CSPC's market value exceeded 100 billion for the first time.
Jin Youli won the "China Patent Gold Award".
"Mitoxantrone hydrochloride liposome" has been approved by the US FDA as an orphan drug for peripheral T-cell lymphoma.
CSPC has signed three overseas product technology licensing and commercialization cooperation agreements for high-end generic drugs.
Hebei Shiyao Puen Charity Foundation was established.
The “Construction of CSRC Pharmaceutical R & D and Innovation System” completed under the auspices of CSPC won the National Scientific and Technological Progress Enterprise Technology Innovation Project Award.
CSPC's Enbipu project was awarded the "China Industrial Award" and is the only pharmaceutical company that has won the "China Industrial Award" in previous evaluations.
CSPC's Central Pharmaceutical Research Institute's "International New-type Preparations and Biomedical International Scientific and Technological Cooperation Base" was identified as "National Model International Scientific and Technological Cooperation Base" by the Ministry of Science and Technology.
CSPC's "L-amlodipine maleate raw material and preparation and industrial application" project won the second prize of the National Technology Invention Award.
The State Key Laboratory of New Drug Preparations and Excipients and the Central Pharmaceutical Research Institute of CSPC opened.
The patent of "butadiene soft capsule and its preparation process" won the China Patent Award.
"National Joint Local Engineering Laboratory for Chiral Drug Development" was awarded by the National Development and Reform Commission.
CSPC was awarded the title of "National Innovative Enterprise".
The Base Construction Division and the Basic Research Division of the Basic Research Department of the Ministry of Science and Technology of China have set up the "National Key Laboratory 973 Special Plan for Enterprises" project, and the "Liposome Drug-Loaded Basic Research" project applied by the Group Pharmaceutical Research Institute has been approved.
At the "2008 Top Ten Domestic and International Environmental News Release Ceremonies", Chairman Cai Dongchen was named China's environmental protection public welfare entrepreneur.
After the Wenchuan earthquake, CSPC donated RMB 12 million in medicine and cash for the first time, and its employees donated RMB 1.07 million. Professor Cui Liying of Xiehe Hospital led the “Eleventh Five-Year Plan” National Scientific and Technological Support Program “Standardized Study on Intervention of Intracranial and External Arterial Stenosis and Secondary Prevention of Stroke”, and the “Enbipu Secondary Prevention Research” project was listed as one of the national research topics.
CSPC won the Love Award of China Environmental Protection Enterprise.
CSPC's VC series products obtained the COS certification certificate signed by the European Medicines Quality Council (EDQM), which is the first time that a domestic VC manufacturing company has passed the COS certification.
Assessed by the World Brand Lab (WBL), the "Shiyao" brand was selected as the "2005 (Second) 500 Most Valuable Brands in China".
The national "Tenth Five-Year" 863 major science and technology project, the national first-class new drug Enbipu was listed.
The State Administration for Industry and Commerce recognized CSPC as the well-known trademark in China.
CSPC's listing in Hong Kong-China Pharmaceuticals was rated as "200 outstanding companies with a turnover of less than one billion US dollars worldwide (except the US) in 2003 by Forbes".
Trial production of national first-class new drug "butylphthalide".
The implementation of the enzymatic method 7-ACA expansion project has filled the domestic gap.
CSPC's postdoctoral research station was established.
Chairman Cai Dongchen won the title of National Model Worker.
Cai Dongchen was elected as the representative of the Ninth National People's Congress.
On August 21, CSPC was established, and Cai Dongchen was elected as chairman.
CSPC's predecessor was the Jizhong Military Region Sanitary Material Factory, which was established in Ligezhuang, Renqiu County, Hebei Province, and mainly produces war medical supplies.